Role of CSF biomarkers in the diagnosis of prodromal Alzheimers disease

Biomarkers in Medicine

Volumn 5, Issue 4, 2011, Pages 479-484

  Parnetti, Lucilla ^a   Chiasserini, Davide ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Alzheimer's disease; amyloid protein; biomarkers; cerebrospinal fluid; mild cognitive impairment; phosphorylated tau; total tau; variability

Indexed keywords

ALPHA SECRETASE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; BIOLOGICAL MARKER; CHITINASE; CHITINASE 3 LIKE PROTEIN 1; FATTY ACID BINDING PROTEIN; GAMMA SECRETASE; HEART FATTY ACID BINDING PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BIOACCUMULATION; BRAIN ATROPHY; BRAIN REGION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL PRACTICE; CORRELATIONAL STUDY; DIAGNOSTIC TEST; HIPPOCAMPUS; HUMAN; NERVE DEGENERATION; NEUROPATHOLOGY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOLOGICAL MARKERS; EARLY DIAGNOSIS; HUMANS; MILD COGNITIVE IMPAIRMENT; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 80052075022     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.11.48     Document Type: Review

References (48)

1. Blennow K, De Leon Mj, Zetterberg H: Alzheimer's disease. Lancet 368(9533), 387-403 (2006). (Pubitemid 44108123)
2. Jack Jr CR, Knopman DS, Jagust WJ et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 9(1), 119-128 (2010).
3. Petersen RC. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256(3), 183-194 (2004). (Pubitemid 39222988)
4. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch. Neurol. 56(3), 303-308 (1999). (Pubitemid 29120227)
5. Walsh DM, Tseng BP, Rydel RE, Podlisny MB, Selkoe DJ. The oligomerization of amyloid b-protein begins intracellularly in cells derived from human brain. Biochemistry 39(35), 10831-10839 (2000).
6. Manfredi G, Beal MF. The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain pathol. (Zurich, Switzerland) 10(3), 462-472 (2000). (Pubitemid 30431299)
7. Zhu X, Raina AK, Perry G, Smith MA. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 3(4), 219-226 (2004). (Pubitemid 38373660)
8. Deane R, Sagare A, Hamm K et al. apoE isoform-specifc disruption of amyloid b peptide clearance from mouse brain. J. Clin. Invest. 118(12), 4002-4013 (2008).
9. Furukawa K, Sopher BL, Rydel RE et al. Increased activity-regulating and neuroprotective effcacy of a-secretase-derived secreted amyloid precursor protein conferred by a C-terminal heparin-binding domain. J. Neurochem. 67(5), 1882-1896 (1996). (Pubitemid 26349661)
10. Olsson A, Hoglund K, Sjogren M et al. Measurement of a-and b-secretase cleaved amyloid precursor protein in cerebrospinal fuid from Alzheimer patients. Exper. Neurol. 183(1), 74-80 (2003). (Pubitemid 37075858)
11. Lewczuk P, Kamrowski-Kruck H, Peters O et al. Soluble amyloid precursor proteins in the cerebrospinal fuid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol. Psych. 15(2), 138-145 (2010).
12. Jarrett JT, Berger EP, Lansbury PT Jr. The C-terminus of the b protein is critical in amyloidogenesis. Ann. NY Acad. Sci. 695, 144-148 (1993).
13. Strozyk D, Blennow K, White LR, Launer LJ: CSF Aβ 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60(4), 652-656 (2003). (Pubitemid 36246085)
14. Fagan AM, Mintun MA, Mach RH et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fuid Aβ42 in humans. Ann. neurol. 59(3), 512-519 (2006). (Pubitemid 43358072)
15. Forsberg A, Engler H, Almkvist O et al. PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol. Aging 29(10), 1456-1465 (2008).
16. Lee G, Rook SL. Expression of t protein in non-neuronal cells: microtubule binding and stabilization. J. Cell Sci. 102(Pt 2), 227-237 (1992).
17. Andreadis A, Brown WM, Kosik KS. Structure and novel exons of the human t gene. Biochemistry 31(43), 10626-10633 (1992).
18. Iqbal K, Alonso Adel C, Chen S et al. t pathology in Alzheimer disease and other topathies. Biochim. Biophysica acta. 1739(2-3), 198-210 (2005). (Pubitemid 40018538)
19. Tapiola T, Alafuzoff I, Herukka SK et al. Cerebrospinal fuid {b}-amyloid 42 and t proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch. Neurol. 66(3), 382-389 (2009).
20. Samgard K, Zetterberg H, Blennow K, Hansson O, Minthon L, Londos E. Cerebrospinal fuid total t as a marker of Alzheimer's disease intensity. Int. J. Geriatric Psychiatry 25(4), 403-410 (2010).
21. Blom ES, Giedraitis V, Zetterberg H et al. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of t in cerebrospinal fuid and the APOE e4/e4 genotype. Dement. Geriat. Cogn. Disord. 27(5), 458-464 (2009).
22. Buerger K, Ewers M, Pirttila T et al. CSF phosphorylated t protein correlates with neocortical neurofbrillary pathology in Alzheimer's disease. Brain 129(Pt 11), 3035-3041 (2006). (Pubitemid 44684523)
23. Holsinger RM, Mclean CA, Collins SJ, Masters CL, Evin G. Increased [b]-secretase activity in cerebrospinal fuid of Alzheimer's disease subjects. Ann. Neurol. 55, 898-899 (2004). (Pubitemid 38702591)
24. Zetterberg H: Elevated cerebrospinal fuid BACE1 activity in incipient Alzheimer disease. Arch. Neurol. 65, 1102-1107 (2008).
25. Zhong Z. Levels of [b]-secretase (BACE1) in cerebrospinal fuid as a predictor of risk in mild cognitive impairment. Arch. Gen. Psychiatry 64, 718-726 (2007). (Pubitemid 46878672)
26. Wu G, Sankaranarayanan S, Tugusheva K et al. Decrease in age-adjusted cerebrospinal fuid b-secretase activity in Alzheimer's subjects. Clin. Biochem. 41(12), 986-996 (2008).
27. Ewers M, Cheng X, Nural HF et al. Increased CSF-BACE1 activity associated with decreased Hippocampus volume in Alzheimer's disease. J. Alzheimers Dis. (2010).
28. Mulder SD, Van Der Flier WM, Verheijen JH et al. BACE1 activity in cerebrospinal fuid and its relation to markers of AD pathology. J. Alzheimers Dis. 20(1), 253-260 (2010).
29. Hansson O. Prediction of Alzheimer's disease using the CSF A[b]42/A[b]40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23, 316-320 (2007). (Pubitemid 46631938)
30. Mehta PD. Plasma and cerebrospinal fuid levels of amyloid [b] proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57, 100-105 (2000). (Pubitemid 30027637)
31. Chiasserini D, Parnetti L, Andreasson U et al. CSF levels of heart fatty acid binding protein are altered during early phases of Alzheimer's disease. J. Alzheimers Dis. 22(4), 1281-1288 (2010).
32. Hu WT, Chen-Plotkin A, Arnold SE et al. Novel CSF biomarkers for Alzheimer's disease and mild cognitive impairment. Acta. Neuropathologica 119(6), 669-678 (2010).
33. Rosen C, Mattsson N, Johansson PM et al. Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases. Frontier Aging Neurosci. 3, 1 (2011).
34. Teunissen CE, Veerhuis R, De Vente J et al. Brain-specifc fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. Eur. J. Neurol, (2010).
35. Johansen JS. Studies on serum YKL-40 as a biomarker in diseases with infammation, tissue remodelling, fbroses and cancer. Danish Med. Bull. 53(2), 172-209 (2006). (Pubitemid 43772025)
36. Johansen JS, Schultz NA, Jensen BV. Plasma YKL-40: a potential new cancer biomarker? Future Oncol. (Lond., UK) 5(7), 1065-1082 (2009).
37. Craig-Schapiro R, Perrin RJ, Roe CM et al. YKL-40: a novel prognostic fuid biomarker for preclinical Alzheimer's disease. Biol. Psych. 68(10), 903-912 (2010).
38. Perrin RJ, Craig-Schapiro R, Malone JP et al. Identifcation and validation of novel cerebrospinal fuid biomarkers for staging early Alzheimer's disease. PloS One 6(1), E16032 (2011).
39. Consensus report of the working group on: "Molecular and biochemical markers of Alzheimer's disease". The Ronald and Nancy Reagan research institute of the Alzheimer's association and the national institute on aging working group. Neurobiol. Aging 19(2), 109-116 (1998).
40. Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD patients using p-amyloid(1-42) and x levels in CSF. Neurology 52(8), 1555-1562 (1999). (Pubitemid 29220627)
41. Schott JM, Bartlett JW, Fox NC, Barnes J. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fuid Ap1-42. Ann. Neurol. 68(6), 825-834 (2010).
42. Mattsson N, Zetterberg H, Hansson O et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302(4), 385-393 (2009).
43. Verwey NA, Van Der Flier WM, Blennow K et al. A worldwide multicentre comparison of assays for cerebrospinal fuid biomarkers in Alzheimer's disease. Ann. Clin. Biochem. 46(Pt 3), 235-240 (2009).
44. Lewczuk P, Beck G, Ganslandt O et al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett. 409(1), 1-4 (2006). (Pubitemid 44740057)
45. Mattsson N, Zetterberg H, Blennow K. Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease. Int. J. Alzheimers Dis. 2010, 610613 (2010).
46. Teunissen CE, Verwey NA, Kester MI, Van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid b((1-42)), t, and phosphorylated t in Alzheimer's disease: Report of an international workshop. Int. J. Alzheimers Dis. 2010, 635053 (2010).
47. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 34(7), 939-944 (1984). (Pubitemid 14076461)
48. Mattsson N, Zetterberg H. Alzheimer's disease and CSF biomarkers: key challenges for broad clinical applications. Biomarkers Med. 3(6), 735-737 (2009).